Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Sep 7, 2021

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatment options for a heart condition called Ventricular Tachycardia (VT), which causes the heart to beat too fast. The study focuses on the current standard treatment, known as catheter ablation, where doctors use a thin tube to remove the problem area in the heart. In contrast, the trial is also exploring a newer method called radio-ablation, which uses radiation to target the VT without needing to insert anything into the body. This new approach uses advanced technology to map out the heart's circuits, helping doctors precisely target where the VT occurs.

To participate in this trial, you need to be at least 55 years old and have a specific type of heart muscle disease, along with ongoing VT problems despite previous treatments. The trial is open to anyone fitting these criteria, regardless of gender. If eligible and you choose to participate, you can expect to undergo either of the two treatment methods and be monitored closely by the research team. It's important to know that certain conditions, like severe heart failure or being pregnant, may prevent you from joining the trial. Overall, this study aims to find out if the new non-invasive method is as effective as the traditional approach, potentially offering a safer option for patients with VT.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient aged ≥55 years of age
• • 2. Cardiomyopathy (Left ventricular ejection fraction ≤ 35% and ICD in situ) AND
• • 3. Recurrent VT events despite previous CA OR
• • 4. VT events requiring intervention and PAINESD score ≥ 15
• Exclusion Criteria:
• • 1. Patients with NYHA Class IV heart failure \&/ or with LVAD in situ
• • 2. Patients not expected to live for more than one year for any reason
• • 3. Patients who have previously received thoracic radiotherapy
• • 4. Patients who are enrolled in another randomized clinical trial
• • 5. Patients who are unable or unwilling to provide informed consent
• • 6. Patients aged ≤54 years of age
• • 7. Pregnancy (all women of child bearing age and potential will have a negative β-HCG test before enrollment)
• • 8. Breastfeeding
• • 9. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception (IUD, sterilization, birth control implant or birth control pill) throughout the study.